Xeltis Launches aXess Commercial Rollout
EINDHOVEN, The Netherlands, July 7, 2026 Xeltis has announced the first commercial implantation of its aXess™ vascular access device,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
EINDHOVEN, The Netherlands, July 7, 2026 Xeltis has announced the first commercial implantation of its aXess™ vascular access device,...
EINDHOVEN, The Netherlands, July 2, 2026 Xeltis announced that it has surpassed 50% patient enrollment in its U.S. pivotal...
LONDON, April 23, 2026 In a significant advancement for vascular access treatment, FLEX Vascular has announced 12-month real-world outcomes...
MISSISSAUGA, Ontario, April 15, 2026 Covalon Technologies Ltd. has reported a series of significant milestones across vascular access, infection...
MISSISSAUGA, Ontario, Feb. 19, 2026 — Covalon Technologies Ltd. announced a strategic educational collaboration with the Association for Vascular...
Fort Lauderdale, FL – September 4, 2025 – The first U.S. clinical cases using the CERTA™ Access System, a...
MINNEAPOLIS, August 29, 2025 — Phraxis announced the successful completion of the first-ever commercial case using its EndoForce Anastomotic...
